Merrimack Pharmaceuticals Inc (MACK) May Be Right For Your Portfolio

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) may be the perfect biotech company for your speculative portfolio. The company had its Initial Public Offering in March of 2012 and raised $100 million for its operations. The sale of the public offering was at $7 dollars a share, valuing the company at $647 million. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) seems to have come to market at the right time, as it currently has eight drugs in it’s portfolio to bring long term value for investors. The price of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has been stagnant since its initial public offering as investors await for results from its late stage cancer trials.

Partnership

Biotech stocks that are at an early stage have a lot of trouble with raising capital and obtaining funding for trials. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) is in a good spot as it already has two partnerships for it’s drug portfolio. MM-121 is one of these compounds–it is a monoclonal antibody that targets the ERbB3 cell surface receptor, and is partnered with Sanofi SA (ADR) (NYSE:SNY) for multiple cancer indications like ovarian cancer, breast cancer, and NSCLC cancer. MM-398 is the lead candidate for Merrimack as it is in a phase three trial for metastatic pancreatic cancer for patients who had previously failed treatment with Gemcitabine. It is partnered with Pharmengine, who hold rights in Taiwan for the drug. The best part about Merrimack’s MM-398 is that the FDA has granted it an orphan drug designation.

Pancreatic Cancer Market

To this day pancreatic cancer is one of the hardest forms of cancer to treat. The five year survival rate for people living with the disease is around 4% and the current therapies are toxic. The current therapies for pancreatic cancer aren’t extending the life of patients for long and more drugs are needed for this indication. If Merrimack Pharmaceuticals Inc (NASDAQ:MACK) is successful in their phase three trial for MM-398 the company would have a huge market opportunity, as the pancreatic cancer market is set to be worth about $1.2 billion dollars by the year 2015.

Competitors

Merrimack faces some competition in the pancreatic cancer space. Two competing companies are Celgene Corporation (NASDAQ:CELG) and Threshold Pharmaceuticals, Inc. (NASDAQ:THLD). Celgene announced in January of 2013 that patients who took the company’s drug Abraxane with Gemcitabine lived for 8.5 months longer, compared to those who took Gemcitabine alone and survived only 6.7 months. That’s a life extension of 1.8 months of patients who took Abraxane, which is better than standard care alone. Threshold has a drug that is currently in a phase 3 trial for pancreatic cancer, but in it’s phase 2 trial it reported a better life extension than Celgene’s Abraxane. Threshold reported a life extension of 9.2 months for patients treated with TH-302 compared to Gemcitabine alone at 6.7 months. Obviously Merrimack will have some competition in this space, but the company’s success or failure all depends on what they finally report in their phase three result of MM-398.

Final Thoughts

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has an array of cancer drugs in its pipeline that could bring lots of value for long term investors. It has been able to provide an initial public offering to provide adequate funding for their late stage trials and other administrative expenses. The pancreatic cancer market will grow to $1.2 billion dollars in 2015 and that could bring a huge opportunity for long term investors in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). If all goes well with MM-398 then the company’s valuation will be reevaluated to be higher because of the market potential for the drug. Investors should be aware of the fact that pancreatic cancer is the hardest form of cancer to treat, so the chances that the results will be outstanding will be small, but patience is needed in this biotech name.

The article Merrimack May Be Right For Your Portfolio originally appeared on Fool.com and is written by Terry Chrisomalis.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!